

**Oncology Clinical Trials**  
**Penn Medicine Lancaster General Health, Ann B. Barshinger Cancer Institute**

	<b>Study Title – updated 4/19/21</b>
<b>BRAIN</b>	
<b>NRG-BN007</b>	A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide In Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
<b>BREAST</b>	
<b>Metamorph- Penn</b>	Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
<b>NRG-BR004</b>	NRG BR004: A randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
<b>CCTG MA-39</b>	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
<b>GASTRIC</b>	
<b>SPOTLIGHT: 8951-CL-0301</b>  <b>ASTELLAS</b>	Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus MFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
<b>LUNG</b>	
<b>BMS CA 224-104</b> <b>Relativity</b>	A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
<b>NRG-LU005</b>	Limited Stage Small Cell Lung Cancer(LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
<b>NRG-LU002</b>	Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
<b>OVARIAN</b>	
<b>NRG-GY009</b>	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin And CTEP-Supplied Atezolizumab(IND#134427) Versus Pegulated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer
<b>NRG-GY020</b>	A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

**Oncology Clinical Trials**  
**Penn Medicine Lancaster General Health, Ann B. Barshinger Cancer Institute**

<b>HEMATOLOGY</b>	
<b>STOP-CA-Penn</b>	Statins TO Prevent the Cardiotoxicity from Anthracyclines
<b>Connect AML-MDS Registry Celgene</b>	Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
<b>OTHER</b>	
<b>EAY131-MATCH ECOG</b>	Molecular Analysis for Therapy Choice (MATCH)
<b>PROMPT- Penn</b>	Prospective Registry of MultiPlex Testing
<b>ASCO COVID Registry</b>	ASCO Survey on COVID-19 Oncology (ASCO) Registry
<b>MTG 022 MT Group</b>	Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients